1. |
Sullivan LS, Daiger SP. Inherited retinal degeneration: exceptional genetic and clinical heterogeneity[J]. Mol Med Today, 1996, 2(9): 380-386. DOI: 10.1016/s1357-4310(96)10037-x.
|
2. |
Xu L, Hu L, Ma K, et al. Prevalence of retinitis pigmentosa in urban and rural adult Chinese: The Beijing Eye Study[J]. Eur J Ophthalmol, 2006, 16(6): 865-866. DOI: 10.1177/112067210601600614.
|
3. |
国家发展和改革委员会. 中华人民共和国国民经济和社会发展第十四个五年规划和2035年远景目标纲要[EB/OL]. (2021-03-12)[2022-08-08]. http://www.gov.cn/xinwen/2021-03/13/content_5592681.htm.National Development and Reform Commission. Outline of the 14th Five-Year Plan for National Economic and Social Development of the People's Republic of China and the Vision for 2035[EB/OL]. (2021-03-12)[2022-08-08]. http://www.gov.cn/xinwen/2021-03/13/content_5592681.htm.
|
4. |
上海市人民政府办公厅. 上海市先进制造业发展“十四五”规划(第12号)[EB/OL]. (2021-07-05)[2022-08-08]. https://www.shanghai.gov.cn/nw12344/20210714/0a62ea7944d34f968ccbc49eec47dbca.html.General Office of Shanghai Municipal People's Government. "14th Five-Year Plan" for the Development of Advanced Manufacturing Industry in Shanghai (No. 12)[EB/OL]. (2021-07-05)[2022-08-08]. https://www.shanghai.gov.cn/nw12344/20210714/0a62ea7944d34f968ccbc49eec47dbca.html.
|
5. |
北京市人民政府办公厅. 北京市“十四五”时期高精尖产业发展规划(第21号)[EB/OL]. (2021-08-11)[2022-08-08]. http://www.beijing.gov.cn/zhengce/zhengcefagui/202108/t20210818_2471375.html.General Office of Beijing Municipal People's Government. Beijing's "14th Five-Year Plan" period high-tech industry development plan (No. 21)[EB/OL]. (2021-08-11)[2022-08-08]. http://www.beijing.gov.cn/zhengce/zhengcefagui/202108/t20210818_2471375.html.
|
6. |
Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN[J]. Hum Gene Ther, 2018, 29(3): 285-298. DOI: 10.1089/hum.2018.015.
|
7. |
Philippidis A. Fourth boy dies in clinical trial of Astellas' AT132[J]. Hum Gene Ther, 2021, 32(19-20): 1008-1010. DOI: 10.1089/hum.2021.29182.bfs.
|
8. |
Greenberg B, Butler J, Felker GM, et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure[J]. Gene Ther, 2016, 23(3): 313-319. DOI: 10.1038/gt.2015.109.
|
9. |
Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis[J]. N Engl J Med, 2015, 372(20): 1887-1897. DOI: 10.1056/NEJMoa1414221.
|
10. |
Boyd RF, Boye SL, Conlon TJ, et al. Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs[J]. Gene Ther, 2016, 23(6): 548-556. DOI: 10.1038/gt.2016.31.
|
11. |
Fischer MD, Ochakovski GA, Beier B, et al. Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial[J]. JAMA Ophthalmol, 2019, 137(11): 1247-1254. DOI: 10.1001/jamaophthalmol.2019.3278.
|
12. |
Ye GJ, Budzynski E, Sonnentag P, et al. Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-PR1.7-hCNGB3, a recombinant AAV vector for treatment of achromatopsia[J]. Hum Gene Ther Clin Dev, 2016, 27(1): 37-48. DOI: 10.1089/humc.2015.164.
|
13. |
国家药监局药审中心. 罕见疾病药物临床研发技术指导原则(第71号)[EB/OL]. (2022-01-06)[2022-08-08]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20220601110541120.html.Drug Evaluation Center of the State Food and Drug Administration. Technical Guidelines for Clinical Research and Development of Rare Disease Drugs (No. 71)[EB/OL]. (2022-01-06)[2022-08-08]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20220601110541120.html.
|
14. |
中国眼遗传病诊疗小组, 中国眼科遗传联盟. 眼遗传病基因诊断方法专家共识[J]. 中华实验眼科杂志, 2018, 36(7): 481-488. DOI: 10.3760/cma.j.issn.2095-0160.2018.07.001.Chinese Eye Genetic Diseases Diagnosis and Treatment Group, China Eye Genetics Alliance. Expert consensus on genetic diagnosis methods for eye genetic diseases[J]. Chin J Exp Ophthalmol, 2018, 36(7): 481-488. DOI: 10.3760/cma.j.issn.2095-0160.2018.07.001.
|
15. |
Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis[J]. N Engl J Med, 2008, 358(21): 2231-2239. DOI: 10.1056/NEJMoa0802268.
|
16. |
彭晓燕, 张永鹏. 正确合理使用糖皮质激素: 一个眼底病治疗中仍需重视的问题[J]. 中华眼底病杂志, 2011, 27(3): 207-209. DOI: 10.3760/cma.j.issn.1005-1015.2011.03.002.Peng XY, Zhang YP. Think twice before you go: some issues of corticosteroid application in the treatment of ocular fundus diseases[J]. Chin J Ocul Fundus Dis, 2011, 27(3): 207-209. DOI: 10.3760/cma.j.issn.1005-1015.2011.03.002.
|
17. |
Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial[J]. Lancet, 2009, 374(9701): 1597-1605. DOI: 10.1016/S0140-6736(09)61836-5.
|
18. |
Maguire AM, Russell S, Wellman JA, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials[J]. Ophthalmology, 2019, 126(9): 1273-1285. DOI: 10.1016/j.ophtha.2019.06.017.
|
19. |
Bucher K, Rodríguez-Bocanegra E, Dauletbekov D, et al. Immune responses to retinal gene therapy using adeno-associated viral vectors-implications for treatment success and safety[J/OL]. Prog Retin Eye Res, 2021, 83: 100915[2020-10-15]. https://pubmed.ncbi.nlm.nih.gov/33069860/. DOI: 10.1016/j.preteyeres.2020.100915.
|
20. |
Cideciyan AV, Jacobson SG, Drack AV, et al. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect[J]. Nat Med, 2019, 25(2): 225-228. DOI: 10.1038/s41591-018-0295-0.
|
21. |
Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis[J]. Ophthalmology, 1985, 92(4): 467-471. DOI: 10.1016/s0161-6420(85)34001-0.
|
22. |
Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop[J]. Am J Ophthalmol, 2005, 140(3): 509-516. DOI: 10.1016/j.ajo.2005.03.057.
|
23. |
Bouquet C, Vignal Clermont C, Galy A, et al. Immune response and intraocular inflammation in patients with Leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1/2 clinical trial[J]. JAMA Ophthalmol, 2019, 137(4): 399-406. DOI: 10.1001/jamaophthalmol.2018.6902.
|
24. |
杨培增. 关注我国葡萄膜炎的病因和类型的变化[J]. 中华眼科杂志, 2008, 44(10): 865-866. DOI: 10.3321/j.issn:0412-4081.2008.10.001.Yang PZ. Concern on the changes of clinical pattern and etiological factors in uveitis in China[J]. Chin J Ophthalmol, 2008, 44(10): 865-866. DOI: 10.3321/j.issn:0412-4081.2008.10.001.
|
25. |
Cukras C, Wiley HE, Jeffrey BG, et al. Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase Ⅰ/Ⅱa trial by intravitreal delivery[J]. Mol Ther, 2018, 26(9): 2282-2294. DOI: 10.1016/j.ymthe.2018.05.025.
|
26. |
Gange WS, Sisk RA, Besirli CG, et al. Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis[J]. Ophthalmol Retina, 2022, 6(1): 58-64. DOI: 10.1016/j.oret.2021.03.016.
|
27. |
中华医学会眼科学分会眼底病学组, 中华医学会眼科学分会白内障及屈光手术学组中华医学会眼科学分会眼外伤学组, 中华医学会眼科学分会青光眼学组. 中国眼科手术后感染性眼内炎诊疗专家共识(2022年)[J]. 中华眼科杂志, 2022, 58(7): 487-499. DOI: 10.3760/cma.j.cn112142-20220301-00088.Fundus Diseases Group of Ophthalmology Branch of Chinese Medical Association, Cataract and Refractive Surgery Group of Ophthalmology Branch of Chinese Medical Association, Eye Trauma Group of Ophthalmology Branch of Chinese Medical Association, Glaucoma Group of Ophthalmology Branch of Chinese Medical Association. Chinese expert consensus on the diagnosis and management of infectious endophthalmitis after ophthalmic surgery (2022)[J]. Chin J Ophthalmol, 2022, 58(7): 487-499. DOI: 10.3760/cma.j.cn112142-20220301-00088.
|
28. |
Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017, 390(10097): 849-860. DOI: 10.1016/S0140-6736(17)31868-8.
|